Oncogenic osteomalacia in a case with a maxillary sinus mesenchymal tumor

被引:25
作者
Koriyama, Nobuyuki
Nishimoto, Kengo
Kodama, Takuro
Nakazaki, Mitsuhiro
Kurono, Yuichi
Yoshida, Hiroki
Tei, Chuwa
机构
[1] Natl Hosp Org, Kagoshima Med Ctr, Dept Diabet & Endocrine Med, Kagoshima 8920853, Japan
[2] Kagoshima Univ Hosp, Dept Diabet & Endocrine Med, Kagoshima, Japan
[3] Kagoshima Univ Hosp, Dept Otolaryngol, Kagoshima, Japan
[4] Kagoshima Univ Hosp, Dept Tumor Pathol, Kagoshima, Japan
[5] Kagoshima Univ Hosp, Dept Cardiovasc Med, Kagoshima, Japan
关键词
oncogenic; osteomalacia; mesenchymal tumor; FGF23; hypophosphatemia;
D O I
10.1097/00000441-200609000-00010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We herein describe the rare case of a 41-year-old woman with oncogenic osteomalacia due to a tumor in the maxillary sinus who presented with chronic general pain that had been gradually deteriorating. The patient's laboratory findings revealed hypophosphatemia due to renal phosphate wasting, an inappropriately low serum I a,25-dihydroxyvitamin D-3 level for hypophosphatemia and an unusually high serum level of fibroblast growth factor 23 (FGF23). The causative tumor was surgically removed, resulting in a rapid resolution of the patient's biochemical abnormalities. An improvement of the abnormal multiple deposits on (99)Technetium-methylene diphosphonate bone scintigraphy and an increase in the bone metabolism markers suggested the development of bone remodeling within 49 days after the operation. The pathologic diagnosis of the tumor was a "phosphaturic mesenchymal tumor, mixed with a connective tissue variant." The expression of FGF23 was demonstrated in the tumor by the immunohistochemical techniques and a Western analysis.
引用
收藏
页码:142 / 147
页数:6
相关论文
共 28 条
  • [11] MCCANCE RA, 1947, Q J MED, V16, P33
  • [12] Regulation of Na/Pi transporter in the proximal tubule
    Murer, H
    Hernando, N
    Forster, I
    Biber, J
    [J]. ANNUAL REVIEW OF PHYSIOLOGY, 2003, 65 : 531 - 542
  • [13] Clinical case seminar -: Fibroblast growth factor 23:: A new clinical marker for oncogenic osteomalacia
    Nelson, AE
    Bligh, RC
    Mirams, M
    Gill, A
    Au, A
    Clarkson, A
    Jüppner, H
    Ruff, S
    Stalley, P
    Scolyer, RA
    Robinson, BG
    Mason, RS
    Bligh, PC
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09) : 4088 - 4094
  • [14] Nguyen BD, 1999, CLIN NUCL MED, V24, P130
  • [15] PRADER A, 1959, Helv Paediatr Acta, V14, P554
  • [16] Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy
    Rhee, Y
    Lee, JD
    Shin, KH
    Lee, HC
    Huh, KB
    Lim, SK
    [J]. CLINICAL ENDOCRINOLOGY, 2001, 54 (04) : 551 - 554
  • [17] STUDIES IN A PATIENT WITH TUMOR-INDUCED HYPOPHOSPHATEMIC OSTEOMALACIA
    RYAN, WG
    GITELIS, S
    CHARTERS, JR
    [J]. CALCIFIED TISSUE INTERNATIONAL, 1986, 38 (06) : 358 - 362
  • [18] Human fibroblast growth factor-23 mutants suppress Na+ -dependent phosphate co-transport activity and 1α,25-dihydroxyvitamin D3 production
    Saito, H
    Kusano, K
    Kinosaki, M
    Ito, H
    Hirata, M
    Segawa, H
    Miyamoto, K
    Fukushima, N
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (04) : 2206 - 2211
  • [19] Octreotide therapy for tumor-induced osteomalacia
    Seufert, J
    Ebert, K
    Müller, J
    Eulert, J
    Hendrich, C
    Werner, E
    Schütze, N
    Schulz, G
    Kenn, W
    Richtmann, H
    Palitzsch, KD
    Jakob, F
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (26) : 1883 - 1888
  • [20] Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency
    Shigematsu, T
    Kazama, JJ
    Yamashita, T
    Fukumoto, S
    Hosoya, T
    Gejyo, F
    Fukagawa, M
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 44 (02) : 250 - 256